Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03851445 · ClinicalTrials.gov registry record · Phase 2
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
A Phase 2 study of Previously Treated Non-Small Cell Lung Cancer, sponsored by SWOG Cancer Research Network.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10,000
- Enrollment target
- 20
- Study locations
NCT03851445 is a Phase 2 study of Previously Treated Non-Small Cell Lung Cancer that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 10,000 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT03851445, a Phase 2 study of Previously Treated Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by SWOG Cancer Research Network.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Conditions Studied
Interventions
- DRUG Screening Platform
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Alabama
- Veterans Administration Medical Center - Birmingham - Birmingham
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis - Daphne
- Thomas Hospital - Fairhope
- Mobile Infirmary Medical Center - Mobile
- University of South Alabama Mitchell Cancer Institute - Mobile
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland - Saraland
Arizona
- CTCA at Western Regional Medical Center - Goodyear
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2019-02-06 |
| Est. Completion | 2029-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03851445
The ClinicalTrials.gov registry entry for NCT03851445 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Previously Treated Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Screening Platform is the first listed.
NCT03851445 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Alaska, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT03851445 about?
NCT03851445 is a clinical study titled "Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer". This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will deter...
What is the current status of trial NCT03851445?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10,000 participants. The study started on 2019-02-06. Estimated completion is 2029-01-28.
What conditions does trial NCT03851445 study?
This clinical trial studies the following conditions: Previously Treated Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03851445?
The interventions under investigation include: Screening Platform (DRUG).
Who is sponsoring clinical trial NCT03851445?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03851445 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.